368 related articles for article (PubMed ID: 33741847)
1. Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials.
Lee SG; Jeng LB; Saliba F; Singh Soin A; Lee WC; De Simone P; Nevens F; Suh KS; Fischer L; Jin Joo D; Fung J; Joh JW; Kaido T; Grant D; Meier M; Rauer B; Sips C; Kaneko S; Levy G
Transplantation; 2021 Jul; 105(7):1564-1575. PubMed ID: 33741847
[TBL] [Abstract][Full Text] [Related]
2. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
3. Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial.
Nashan B; Schemmer P; Braun F; Schlitt HJ; Pascher A; Klein CG; Neumann UP; Kroeger I; Wimmer P;
Liver Transpl; 2022 Jun; 28(6):998-1010. PubMed ID: 34525259
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma.
Sapisochin G; Lee WC; Joo DJ; Joh JW; Hata K; Soin AS; Veldandi UK; Kaneko S; Meier M; Leclair D; Sunkara G; Jeng LB
Ann Transplant; 2022 Nov; 27():e937988. PubMed ID: 36411723
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
6. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
[TBL] [Abstract][Full Text] [Related]
7. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study.
Jeng LB; Lee SG; Soin AS; Lee WC; Suh KS; Joo DJ; Uemoto S; Joh J; Yoshizumi T; Yang HR; Song GW; Lopez P; Kochuparampil J; Sips C; Kaneko S; Levy G
Am J Transplant; 2018 Jun; 18(6):1435-1446. PubMed ID: 29237235
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
10. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
[TBL] [Abstract][Full Text] [Related]
11. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.
Tönshoff B; Ettenger R; Dello Strologo L; Marks SD; Pape L; Tedesco-Silva H; Bjerre A; Christian M; Meier M; Martzloff ED; Rauer B; Ng J; Lopez P
Am J Transplant; 2019 Mar; 19(3):811-822. PubMed ID: 30125462
[TBL] [Abstract][Full Text] [Related]
12. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.
Gómez-Bravo M; Prieto Castillo M; Navasa M; Sánchez-Antolín G; Lladó L; Otero A; Serrano T; Jiménez Romero C; García González M; Valdivieso A; González-Diéguez ML; de la Mata M; Pons JA; Salcedo M; Rodrigo JM; Cuervas-Mons V; González Rodríguez A; Caralt M; Pardo F; Varo Pérez E; Crespo G; Rubin Á; Guilera M; Aldea A; Santoyo J
Rev Esp Enferm Dig; 2022 Jun; 114(6):335-342. PubMed ID: 35469409
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
14. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
15. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux G; Leroy V; Hardwigsen J; Gharbi H; Masson C; Tindel M; Conti F
Liver Transpl; 2019 Dec; 25(12):1822-1832. PubMed ID: 31631501
[TBL] [Abstract][Full Text] [Related]
16. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
De Simone P; Nevens F; De Carlis L; Metselaar HJ; Beckebaum S; Saliba F; Jonas S; Sudan D; Fung J; Fischer L; Duvoux C; Chavin KD; Koneru B; Huang MA; Chapman WC; Foltys D; Witte S; Jiang H; Hexham JM; Junge G;
Am J Transplant; 2012 Nov; 12(11):3008-20. PubMed ID: 22882750
[TBL] [Abstract][Full Text] [Related]
17. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
18. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux GP; Hardwigsen J; Benkhatar Y; Derquenne F; Conti F
Liver Int; 2022 Nov; 42(11):2513-2523. PubMed ID: 35962772
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
20. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
